missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Adecatumumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

£397.00 - £1002.00

Specifications

Antigen Adecatumumab
Concentration 1 mg/mL
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Applications ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Classification Recombinant Monoclonal
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
30282721
View Documents
Invitrogen™
MA559367
100 μg
£397.00
100µg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
30283979
View Documents
Invitrogen™
MA559368
1 mg
£1002.00
1mg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
Description

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Adecatumumab (MT201) is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has been shown to promote the proliferation, migration and invasiveness of breast cancer cells. Moreover, expression of EpCAM is associated with decreased survival in a number of cancer indications, including breast, gall bladder, bile duct, ovarian and ampullary pancreatic cancer. EpCAM has recently been shown to be expressed on cancer stem cells from breast, prostate, colon and pancreatic cancer. Clinical studies have shown a favorable safety profile and that clinical activity depends on the EpCAM target expression.
Specifications

Specifications

Adecatumumab
-20°C, Avoid Freeze/Thaw Cycles
Recombinant Monoclonal
Lyophilized
IgG1
Human
MT201
Antibody
1 mg/mL
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Unconjugated
Human
RUO
25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Primary
Protein A
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.